Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

CMS proposes Medicare coverage for T-TEER
CMS has proposed covering tricuspid TEER for patients who present with symptomatic tricuspid regurgitation despite optimal medical therapy. The agency still has questions about the available data, however, and is seeking public comments as it makes its final decision.
Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS
Two separate studies at ACC.25 explored data from the EARLY TAVR trial. One analysis included stroke findings that surprised researchers.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Bringing state-of-the-art healthcare to Florida heart patients
Naples Comprehensive Health is building up what it hopes will be a nationally recognized cardiology program. Robert Cubeddu, MD, and Dee Dee Wang, MD, spoke with Cardiovascular Business about the journey so far.

The Pioneer TAVR system from KOKA Lifesciences

New TAVR system for pure aortic regurgitation used for first time, linked to ‘excellent’ short-term outcomes

Researchers explored data from the first 10 patients treated with a new self-expanding TAVR device from KOKA Lifesciences. After 30 days, there were no patient deaths and only one adverse event.

healthcare value value-based care money dollar

Cardiologists, cardiac surgeons push insurance company to rethink billing policy

The American College of Cardiology, Society for Cardiovascular Angiography and Interventions and Society of Thoracic Surgeons raised the issue, which is related to the billing of transcatheter heart procedures such as TAVR.

Stroke after TAVR: New research helps cardiologists detect early warning signs

Post-TAVR stroke is rare, but it can be fatal. A new study in Catheterization and Cardiovascular Interventions examined the issue in great detail, focusing on more than 2,700 patients treated over a two-year stretch.

Death after TAVR: Heart failure, sudden cardiac arrest stand out as 2 leading causes

A majority of patient deaths within two years of TAVR can be linked to cardiovascular complications, according to new research published in JACC: Cardiovascular Interventions. Can follow-up care be improved to combat this trend?

Video of Prof. Dr. Ralph Stephan von Bardeleben explaining the latest details from key tricuspid valve trials.

What new tricuspid valve data tell us about the future of patient care

What are the latest updates on treating tricuspid regurgitation? We spoke with a leading researcher at ESC Congress 2023 to find out.

Warfarin after TAVR is safe, but fails to boost outcomes

Researchers examined two-year data from transfemoral TAVR patients treated with low-dose aspirin and 30 days of warfarin or just aspirin on its own.

EP studies during TAVR are safe and effective, new pilot study confirms

New research in JACC: Cardiovascular Interventions explored the potential of performing EP studies before and after valve deployment. TAVR operators handled all catheter manipulations, and EP specialists were on hand to capture the necessary measurements.

NOACs vs. VKAs in TAVR patients with new-onset AFib: New meta-analysis examines key differences

The biggest differences between the two treatment options were major bleeding events and all-cause mortality. There was no significant difference when it came to stroke risk.

Structural Heart Disease

CMS proposes Medicare coverage for T-TEER

Key takeaways from ACC.25: Advances in cardiovascular science

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Bringing state-of-the-art healthcare to Florida heart patients